Skip to main content

Advertisement

SpringerLink
Log in

Effect of artesunate on inhibiting proliferation and inducing apoptosis of SP2/0 myeloma cells through affecting NFκB p65

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

The initial treatment of multiple myeloma (MM) experienced a paradigm shift, in the past decade, with the introduction of novel agents such as thalidomide, lenalidomide and bortezomib, leading to improved outcomes. High dose therapy and autologous stem cell transplantation remain an important therapeutic option for patients with MM eligible for the procedure. However, most of these treatment regimens are too expensive for Chinese patients. Therefore, we investigated the effects of artesunate, which is commonly used in the treatment of severe malaria, on inhibition of proliferation and induction of apoptosis of a mouse myeloma cell line SP2/0. The growth inhibition of SP2/0 cell proliferation induced by artesunate (ART) treatment was measured using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method and the rate of apoptosis and cell cycle changes induced by ART were analyzed by flow cytometry. ART-induced morphology changes of apoptosis in SP2/0 cells, as observed by light and transmission electron microscopy. Additionally, DNA laddering, which is a hallmark of apoptosis, was observed by agarose gel electrophoresis of DNA harvested from SP2/0 cells treated with ART. The levels of nuclear factor kappa B p65 (NFκB p65) protein in nucleus and the inhibitor of NFκB (IκBα) in the cytoplasm were measured by western blot analysis and ELISA to evaluate NFκB p65 transcription activity indirectly. The results show that artesunate inhibited the proliferation and induced apoptosis of SP2/0 cells in a dose- and time-dependent manner. Artesunate also increased the proportion of SP2/0 cells in G0/G1 phase, while decreased the proportion of cells in G2/M or S phase. Additionally, artesunate treatment decreased the level of NFκB p65 protein in the nucleus, while increased the level of IκBα protein in the cytoplasm. The present result is the first report to show that artesunate may be useful in the treatment of MM.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

References

  1. Fermand JP, Ravaud P, Chevret S, Divine M, Leblond V, Belanger C, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood. 1998;92:3131–6.

    CAS  PubMed  Google Scholar 

  2. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348:1875–83.

    Article  CAS  PubMed  Google Scholar 

  3. Singhal S, Powles R, Sirohi B, Treleaven J, Kulkarni S, Mehta J. Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma. Bone Marrow Transplant. 2002;30:673–9.

    Article  CAS  PubMed  Google Scholar 

  4. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341:1565–71.

    Article  CAS  PubMed  Google Scholar 

  5. Singhal S, Mehta J. Novel therapies in myeloma. Int J Hematol. 2003;77:226–31.

    Article  CAS  PubMed  Google Scholar 

  6. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, et al. Apoptotic signaling induced by immuno-modulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood. 2002;99:4525–30.

    Article  CAS  PubMed  Google Scholar 

  7. Wu KL, Beksac M, van Droogenbroeck J, Amadori S, Zweegman S, Sonneveld P. Phase II multicenter study of arsenic trioxide, ascorbic acid and dexamethasone in patients with relapsed or refractory multiple myeloma. Haematologica. 2006;91:1722–3.

    CAS  PubMed  Google Scholar 

  8. Pei XY, Dai Y, Grant S. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res. 2004;10:3839–52.

    Article  CAS  PubMed  Google Scholar 

  9. Richardson PG, Barlogie B, Berenson J, Irwin D, Stadtmauer EA, Facon T, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609–17.

    Article  CAS  PubMed  Google Scholar 

  10. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352:2487–98.

    Article  CAS  PubMed  Google Scholar 

  11. Oakervee HE, Popat R, Curry N, Smith P, Morris C, Drake M, et al. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol. 2005;129:755–62.

    Article  CAS  PubMed  Google Scholar 

  12. Adjuik M, Babiker A, Garner P, Olliaro P, Taylor W, White N. Artesunate combinations for treatment of malaria: meta-analysis. Lancet. 2004;363:9–17.

    Article  CAS  PubMed  Google Scholar 

  13. Cumming JN, Ploypradith P, Posner GH. Antimalarial activity of artemisinin (qinghaosu) and related trioxanes: mechanism(s) of action. Adv Pharmacol. 1997;37:253–97.

    Article  CAS  PubMed  Google Scholar 

  14. Dorsey G, Vlahos J, Kamya MR, Staedke SG, Rosenthal PJ. Prevention of increasing rates of treatment failure by combining sulfadoxine-pyrimethamine with artesunate or amodiaquine for the sequential treatment of malaria. J Infect Dis. 2003;188:1231–8.

    Article  CAS  PubMed  Google Scholar 

  15. Van Vugt M, Leonardi E, Phaipun L, Slight T, Thway KL, McGready R, et al. Treatment of uncomplicated multidrug-resistant falciparum malaria with artesunate–atovaquone–proguanil. Clin Infect Dis. 2002;35:1498–504.

    Article  PubMed  Google Scholar 

  16. Efferth T, Dunstan H, Sauerbrey A, Miyachi H, Chitambar CR. The anti-malarial artesunate is also active against cancer. Int J Oncol. 2001;18:767–73.

    CAS  PubMed  Google Scholar 

  17. Efferth T, Sauerbrey A, Olbrich A, Gebhart E, Rauch P, Weber HO, et al. Molecular modes of action of artesunate in tumor cell lines. Mol Pharmacol. 2003;64:382–94.

    Article  CAS  PubMed  Google Scholar 

  18. Efferth T, Benakis A, Romero-Rodriguez MR, Tomicic M, Rauh R, Steinbach D, et al. Enhancement of cytotoxicity of artemisinins toward cancer cells by ferrous iron. Free Radic Biol Med. 2004;37:998–1009.

    Article  CAS  PubMed  Google Scholar 

  19. Posner GH, McRiner AJ, Paik IH, Sur S, Borstnik K, Xie S, et al. Anticancer and antimalarial efficacy and safety of artemisinin-derived trioxane dimers in rodents. J Med Chem. 2004;47:1299–301.

    Article  CAS  PubMed  Google Scholar 

  20. Suzuki A, Shiraki K. Tumor cell “dead or alive”: caspase and surviving regulate cell death, cell cycle and cell survival. Histol Histopathol. 2001;16:583–93.

    CAS  PubMed  Google Scholar 

  21. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, et al. Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood. 2002;99:4079–86.

    Article  CAS  PubMed  Google Scholar 

  22. Berenson JR, Ma HM, Vescio R. The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma. Semin Oncol. 2001;28:626–33.

    Article  CAS  PubMed  Google Scholar 

  23. Hideshima T, Chauhan D, Schlossman R, Richardson P, Anderson KC. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene. 2001;20:4519–27.

    Article  CAS  PubMed  Google Scholar 

  24. Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem. 2002;277:16639–47.

    Article  CAS  PubMed  Google Scholar 

  25. Keifer JA, Guttridge DC, Ashburner BP, Baldwin AS Jr. Inhibition of NF-кB activity by thalidomide through suppression of IкB kinase activity. J Biol Chem. 2001;276:22382–7.

    Article  CAS  PubMed  Google Scholar 

  26. Zhou LF, Zhu Y, Cui XF, Xie WP, Hu AH, Yin KS. Arsenic trioxide, a potent inhibitor of NF-kappaB, abrogates allergen-induced airway hyperresponsiveness and inflammation. Respir Res. 2006;20:146–9.

    Article  Google Scholar 

  27. Lemarie A, Morzadec C, Mérino D, Micheau O, Fardel O, Vernhet L. Arsenic trioxide induces apoptosis of human monocytes during macrophagic differentiation through nuclear factor-kappaB related survival pathway down-regulation. J Pharmacol Exp Ther. 2006;316:304–14.

    Article  CAS  PubMed  Google Scholar 

  28. Liu WM, Strauss SJ, Chaplin T, Shahin S, Propper DJ, Young BD, et al. s-Thalidomide has a greater effect on apoptosis than angiogenesis in a multiple myeloma cell line. Hematol J. 2004;5:247–54.

    Article  CAS  PubMed  Google Scholar 

  29. Russo SM, Tepper JE, Baldwin AS Jr, Liu R, Adams J, Elliott P, et al. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB. Int J Radiat Oncol Biol Phys. 2001;50:183–93.

    Article  CAS  PubMed  Google Scholar 

  30. St Croix B, Florenes VA, Rak JW, Flanagan M, Bhattacharya N, Slingerland JM, et al. Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents. Nat Med. 1996;2:1204–10.

    Article  CAS  PubMed  Google Scholar 

  31. St Croix B, Sheehan C, Rak JW, Flørenes VA, Slingerland JM, Kerbel RS. E-Cadherin-dependent growth suppression is mediated by the cyclin-dependent kinase inhibitor p27 Kip1. J Cell Biol. 1998;142:557–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, The Second Hospital of Hebei Medical University, 215, Heping Xi Road, 050000, Shijiazhuang City, People’s Republic of China

    Shihui Li, Fang Xue, Zhiyong Cheng, Suyun Wang & Ling Pan

  2. Department of Hematology, Affiliated Haikou Hospital, Xiangya School of Medicine, Central South University, Haikou Municipal Hospital, 570208, Haikou, People’s Republic of China

    Xiaoyang Yang

  3. Department of General Surgery, Aviation Central Hospital, No. 3, Anwai Bei Yuan, ChaoYang District, 100012, Peking City, People’s Republic of China

    Fengyong Geng

Authors
  1. Shihui Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fang Xue
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zhiyong Cheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xiaoyang Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Suyun Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Fengyong Geng
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ling Pan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ling Pan.

About this article

Cite this article

Li, S., Xue, F., Cheng, Z. et al. Effect of artesunate on inhibiting proliferation and inducing apoptosis of SP2/0 myeloma cells through affecting NFκB p65. Int J Hematol 90, 513–521 (2009). https://doi.org/10.1007/s12185-009-0409-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-009-0409-z

Keywords

Search

Navigation